Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death

Cell Death and Differentiation

Volumn 22, Issue 7, 2015, Pages 1219-1230

  Vogel, S ^a,b   Borger V ^a,c   Peters, C ^a   Forster M ^a   Liebfried, P ^a   Metzger, K ^b   Meisel, R ^a   Daubener W ^a   Trapp, T ^a   Fischer, J C ^a   Gawaz, M ^b   Sorg, R V ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; SCATTER FACTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; HGF PROTEIN, MOUSE; HMGB1 PROTEIN, MOUSE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MESENCHYMAL STEM CELL; MONOCYTE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; ANIMAL; CARDIAC MUSCLE CELL; CHEMOTAXIS; MALE; MESENCHYMAL STROMA CELL; NECROSIS; PHYSIOLOGY; REGENERATION; SECRETION (PROCESS);

ANIMALS; APOPTOSIS; CHEMOTAXIS; DENDRITIC CELLS; HEPATOCYTE GROWTH FACTOR; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MALE; MESENCHYMAL STROMAL CELLS; MICE; MONOCYTES; MYOCYTES, CARDIAC; NECROSIS; NEURONS; REGENERATION;

EID: 84930572934     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.225     Document Type: Article

References (60)

1. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2011; 223: 177-194.
2. Nakamura T, Sakai K, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 2011; 26(Suppl 1): 188-202.
3. Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 1994; 269: 8966-8970.
4. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004; 22: 405-414.
5. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.
6. Honda S, Kagoshima M, Wanaka A, Tohyama M, Matsumoto K, Nakamura T. Localization and functional coupling of HGF and c-Met/HGF receptor in rat brain: implication as neurotrophic factor. Brain Res Mol Brain Res 1995; 32: 197-210.
7. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
8. Trapp T, Kogler G, El-Khattouti A, Sorg RV, Besselmann M, Focking M et al. Hepatocyte growth factor/C-met-axis mediated tropism of cord blood derived unrestricted somatic stem cells for neuronal injury. J Biol Chem 2008; 283: 32244-32253.
9. Vogel S, Trapp T, Borger V, Peters C, Lakbir D, Dilloo D et al. Hepatocyte growth factor-mediated attraction of mesenchymal stem cells for apoptotic neuronal and cardiomyocytic cells. Cell Mol Life Sci 2010; 67: 295-303.
10. Miyazawa T, Matsumoto K, Ohmichi H, Katoh H, Yamashima T, Nakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Cereb Blood Flow Metab 1998; 18: 345-348.
11. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H. Myocardial protection from ischemia/ reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511-1519.
12. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000; 7: 417-427.
13. Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, De Angelis A et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 2005; 97: 663-673.
14. Heese O, Disko A, Zirkel D, Westphal M, Lamszus K. Neural stem cell migration toward gliomas in vitro. Neuro Oncol 2005; 7: 476-484.
15. Zhu G, Huang L, Song M, Yu Z, Wu X, Zhao X et al. Over-expression of hepatocyte growth factor in smooth muscle cells regulates endothelial progenitor cells differentiation, migration and proliferation. Int J Cardiol 2010; 138: 70-80.
16. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
17. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci 2009; 16: 12-20.
18. Nesselmann C, Ma N, Bieback K, Wagner W, Ho A, Konttinen YT et al. Mesenchymal stem cells and cardiac repair. J Cell Mol Med 2008; 12: 1795-1810.
19. Khubutiya MS, Vagabov AV, Temnov AA, Sklifas AN. Paracrine mechanisms of proliferative, anti-apoptotic and anti-inflammatory effects of mesenchymal stromal cells in models of acute organ injury. Cytotherapy 2014; 16: 579-585.
20. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
21. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ 2014; 21: 216-225.
22. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-113.
23. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
24. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-7515.
25. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
26. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
27. rd CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: C1318-C1325.
28. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
29. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-1528.
30. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761.
31. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377.
32. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209: 551-563.
33. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
34. Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL et al. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010; 30: 243-254.
35. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176: 12-15.
36. Meng E, Guo Z, Wang H, Jin J, Wang J, Wu C et al. High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev 2008; 17: 805-813.
37. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100: 204-212.
38. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 1998; 98: 1355-1357.
39. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002; 30: 783-791.
40. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-574.
41. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009; 86: 609-615.
42. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59-66.
43. Ciucci A, Gabriele I, Percario ZA, Affabris E, Colizzi V, Mancino G. HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity. PLoS One 2011; 6: e23766.
44. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84-91.
45. Lotfi R, Eisenbacher J, Solgi G, Fuchs K, Yildiz T, Nienhaus C et al. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur J Immunol 2011; 41: 2021-2028.
46. Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y et al. PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 2011; 108: 6609-6614.
47. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-1206.
48. Ranzato E, Patrone M, Pedrazzi M, Burlando B. Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem Biophys 2010; 57: 9-17.
49. Kurz SM, Diebold SS, Hieronymus T, Gust TC, Bartunek P, Sachs M et al. The impact of c-met/scatter factor receptor on dendritic cell migration. Eur J Immunol 2002; 32: 1832-1838.
50. Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P. Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood 2000; 95: 3964-3969.
51. Dai S, Sodhi C, Cetin S, Richardson W, Branca M, Neal MD et al. Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 2010; 285: 4995-5002.
52. Bauer EM, Shapiro R, Billiar TR, Bauer PM. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J Biol Chem 2013; 288: 1365-1373.
53. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
54. Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 2008; 181: 4240-4246.
55. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088.
56. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26: 279-289.
57. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27: 909-919.
58. Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 2006; 105: 41-50.
59. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14: 431-441.
60. Borst O, Ochmann C, Schonberger T, Jacoby C, Stellos K, Seizer P et al. Methods employed for induction and analysis of experimental myocardial infarction in mice. Cell Physiol Biochem 2011; 28: 1-12.